Moderna Therapeutics
Dean Liang Glettig is an experienced professional in the biotechnology and pharmaceutical sectors, currently serving as Director, Program Lead, CMC Portfolio Operations at Moderna since May 2023, where responsibilities include leading cross-functional project teams. Previously, Dean held the position of Senior Director of Product Development at Finch Therapeutics Group from April 2016 to April 2023, overseeing the MSAT team and integrating bioprocess activities into product development. Earlier roles include Director of Product Development at Finch Therapeutics Group, Technical Consultant at Vaxess Technologies, and postdoctoral positions at Tufts University and the Massachusetts Institute of Technology. Dean holds a Ph.D. in Bioengineering and Biomedical Engineering from Tufts University, along with an Executive MBA from the Quantic School of Business and Technology, an MS in Chemistry, and a BS in Chemistry from ETH Zurich.
This person is not in any teams
Moderna Therapeutics
125 followers
Moderna Therapeutics is a biotechnology company that is focused on drug discovery and drug development based on messenger RNA.